In:
Frontiers in Oncology, Frontiers Media SA, Vol. 13 ( 2023-3-6)
Abstract:
Minimal residual disease (MRD) monitoring is an important tool to optimally address post-transplant management of acute myeloid leukemia (AML) patients. Methods We retrospectively analyzed the impact of bone marrow CD34+ molecular chimerism and WT1 on the outcome of a consecutive series of 168 AML patients submitted to allogeneic stem cell transplantation. Results The cumulative incidence of relapse (CIR) was significantly lower in patients with donor chimerism on CD34+ cells ≥ 97.5% and WT1 & lt; 213 copies/ABL x 10^4 both at 1 st month (p=0.008 and p & lt;0.001) and at 3 rd month (p & lt;0.001 for both). By combining chimerism and WT1 at 3 rd month, 13 patients with chimerism & lt; 97.5% or WT1 & gt; 213 showed intermediate prognosis. 12 of these patients fell in this category because of molecular chimerism & lt; 97.5% at a time-point in which WT1 was & lt; 213. Conclusions Our results confirm that lineage-specific molecular chimerism and WT1 after allo-SCT (1 st and 3 rd month) are useful MRD markers. When considered together at 3 rd month, CD34+ molecular chimerism could represent an earlier predictor of relapse compared to WT1 . Further studies are necessary to confirm this preliminary observation.
Type of Medium:
Online Resource
ISSN:
2234-943X
DOI:
10.3389/fonc.2023.1133418
DOI:
10.3389/fonc.2023.1133418.s001
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2023
detail.hit.zdb_id:
2649216-7